Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 84

Results For "cell"

2108 News Found

J. B. Chemicals & Pharmaceuticals announces DJSI score of 77
Sustainability | March 06, 2025

J. B. Chemicals & Pharmaceuticals announces DJSI score of 77

This achievement underscores the company’s steadfast commitment to sustainability, corporate responsibility, and ESG excellence


Zydus Lifesciences launches ANVIMO
News | March 06, 2025

Zydus Lifesciences launches ANVIMO

ANVIMO will be available in dosages of 240 mg and 480 mg


Metropolis Healthcare to acquire Agra's Scientific Pathology
Healthcare | March 04, 2025

Metropolis Healthcare to acquire Agra's Scientific Pathology

Metropolis Clinical Pathology will acquire and operate all laboratories and collection centers of Scientific Pathology in Agra and neighbouring towns through a slump sale transaction


GlaxoSmithkline Pharmaceuticals appoints Carson Dalton as Executive VP - Communications and Government Affairs
People | March 04, 2025

GlaxoSmithkline Pharmaceuticals appoints Carson Dalton as Executive VP - Communications and Government Affairs

Carson brings with him over two decades of experience in Communications, Public Affairs, and Sustainability


Biocon Academy conducts 9th Graduation Day
News | March 04, 2025

Biocon Academy conducts 9th Graduation Day

Notably, 36 female students have been placed in Production and Manufacturing roles, reflecting the growing representation of women in core biotech operations


India’s CRDMO sector growth potential at $22 - $25 Billion by 2035: BCG-IPSO Report
News | February 26, 2025

India’s CRDMO sector growth potential at $22 - $25 Billion by 2035: BCG-IPSO Report

Eleven CRDMOs collaborate to form IPSO with the aim to elevate India’s position in the global pharmaceutical value-chain


Granules India acquires Swiss Senn Chemicals to foray into peptide and CDMO business
News | February 22, 2025

Granules India acquires Swiss Senn Chemicals to foray into peptide and CDMO business

The acquisition aligns with Granules' vision to enter the rapidly expanding peptide-based anti-diabetic and anti-obesity market